NTS-polyplex Nanoparticles for Targeted Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy methods for breast cancer and pleural mesothelioma are either risky due to viral vectors or inefficient with nonviral methods, lacking specificity and often affecting healthy cells, which limits their effectiveness in treating invasive and metastatic stages of these cancers.
Innovation Solution
The development of a targeted gene delivery system using NTS-polyplex nanoparticles that specifically target cells expressing the neurotensin receptor (NTSR1), carrying therapeutic or suicide genes to induce apoptosis in cancer cells, thereby reducing tumor progression and metastasis without harming healthy cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If viral vectors are used for gene delivery, then transfection efficiency is improved, but safety and reliability deteriorate due to risks to patients
Solution Approach 1:
The patent employs non-viral polymeric vectors (such as polyethylenimine, polylysine, or dendrimers) that are safer, biodegradable, and do not integrate into the host genome, eliminating the risks associated with viral vectors while maintaining effective gene delivery through transient expression
2Reliability
If nonviral methods are used for gene delivery, then safety is improved, but transfection efficiency and specificity deteriorate
Solution Approach 1:
The patent incorporates targeting moieties (such as antibodies, peptides, or aptamers) conjugated to the polymeric vector that specifically bind to receptors expressed on the surface of cancer cells, enabling selective delivery and transfection of tumor cells while sparing healthy tissues
Solution Approach 2:
The patent uses composite polymeric structures combining cationic polymers with targeting moieties and gene payloads, creating multifunctional vectors that simultaneously ensure safety, specific targeting, and efficient gene delivery to cancer cells
3Productivity
If conventional chemotherapy is used, then tumor growth is reduced, but harmful effects on healthy cells increase
Solution Approach 1:
The patent delivers therapeutic genes specifically to cancer cells through receptor-mediated endocytosis, enabling localized treatment that spares healthy cells from the cytotoxic effects while maintaining effective tumor growth inhibition
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The NTS-polyplex system demonstrates high specificity and efficiency in transfecting breast cancer and mesothelioma cells, effectively reducing tumor growth and metastasis through targeted gene delivery, offering a safer and more effective alternative to conventional chemotherapy.
Implementation Method 1
The strategy is based on the natural cell process of receptor-mediated endocytosis by which the transfer of genetic material is specifically targeted to the cell of interest (target cell) where the binding of a ligand to its receptor occurs on the cell surface producing endocytosis
Implementation Method 2
a fusogenic peptide (as hemagglutinin HA2) and a charyophillic peptide (as Vp1 of SV40) can be coupled thereto
Data Source
Figure 1A~2
Figure 4
Figure 5~6
AI summary
The present invention describes a system of gene carrier nanoparticles capable of specifically internalize into cancer cells, eg, cancer cells involved in breast cancer, in vitro and in vivo. The system described allows the introduction of therapeutic genes specifically into target cells through NSTR1 receptor-mediated endocytosis of said system, making it possible to provide treatment for this type of conditions, for example by systemic, intravenous, or in situ administration.